• DOI:10.1080/10837450.2020.1852570
• Corpus ID: 227077452

Dry powder inhalation formulation of chitosan nanoparticles for co-administration of isoniazid and pyrazinamide

@article{Changsan2020DryPI,
  title={Dry powder inhalation formulation of chitosan nanoparticles for co-administration of isoniazid and pyrazinamide},
  author={Narumon Changsan and Chutima Sinsuebpol},
  journal={Pharmaceutical Development and Technology},
  year={2020},
  volume={26},
  pages={181 - 192}
}

• N. Changsan, Chutima Sinsuebpol
• Published 19 November 2020
• Materials Science
• Pharmaceutical Development and Technology

Abstract Co-loaded isoniazid and pyrazinamide chitosan nanoparticles were formulated using the ionic gelation method. The formulations were adjusted to five mass ratios of tripolyphosphate (TPP) and chitosan at three TPP concentrations. Particle size, polydispersity index, zeta potential, and encapsulation efficiency were used to evaluate all formulations. The results revealed that the ratio of TPP to chitosan had the highest impact in generating chitosan nanoparticles. The selected nanoparticle formulations were freeze-dried, and the obtained dry powders were characterized using scanning electron microscopy, differential scanning calorimetry, X-ray diffraction, and Fourier-transform infrared spectroscopy to confirm the interaction of loaded drug and formulation excipients. The aerosolized performance of dry powders was also evaluated using the Andersen cascade impactor. A mass median aerodynamic diameter of 3.3–3.5 µm, % fine particle fraction of 30–44%, and 92–95% emitted dose were obtained from all formulations. The dry powder formulations were not toxic to the respiratory tract cell lines. Furthermore, they did not provoke alveolar macrophages into producing inflammatory cytokines or nitric oxides, indicating that the formulations are safe and could potentially be used to deliver to respiratory tract for tuberculosis treatment.